Sunday, 18 June 2017 Food allergy mechanisms and biomarkers

292 Pages·2017·2.13 MB·English

by  Jana Mruck

Sunday, 18 June 2017

Oral Abstract Sessions
OAS 01
10:30 - 12:00
Food allergy mechanisms and biomarkers
Hall 3e
Chair: Alexandra Santos, United Kingdom
Chair: Stefania Arasi, Italy
Session roadmap
Roadmap Speaker: Alexandra Santos, United Kingdom
0001 Innate immune hyperactivation in paediatric food allergy
Neeland M. R., Martino D. J., Dang T. D., Koplin J. J., Saffery R., Allen K. J.
Murdoch Childrens Research Institute, Parkville, Australia
0002 Genetic variation at the Th2 immune gene IL13 is associated with IgE -mediated paediatric food allergy
Ashley S. E.1, Martino D.2, Ellis J.2
1. Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany
2. Murdoch Childrens Research Institute, Parkville, Australia
0003 A proposal for the adverse outcome pathway (AOP) for food sensitization
Van Bilsen J. H.1, Sienkiewicz-Szlapka E.2, Lozano-Ojalvo D.3, Willemsen L. E.4, Antunes C.5, Molina E.3, Smit J. J.4,
Wróblewska B.6, Wichers H. J.7, Knol E.8, Ladics G. S.9, Pieters R. H.4, Denery-Papini S.10, Vissers Y. M.11, Bavaro S. L.12, Larré
C.10, Verhoeckx K. C.1, Roggen E. L.13
1. TNO, Zeist, Netherlands, The
2. University of Warmia and Mazury, Olsztyn, Poland
3. Instituto de Investigación en Ciencias de la Alimentación, Madrid, Spain
4. Utrecht University, Utrecht, Netherlands, The
5. University of Evora, Evora, Portugal
6. Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland
7. Wageningen University & Research, Wageningen, Netherlands, The
8. University Medical Center Utrecht, Utrecht, Netherlands, The
9. DuPont Company, Newark, United States
10. INRA, Nantes, France
11. Nestlé Ltd., Nestlé Research Center, Lausanne, Switzerland
12. Institute of Sciences of Food Production-National Research Council, Bari, Italy
13. 3Rs Managing and Consulting ApS, Lyngby, Denmark
0004 Metabolomic phenotyping based biomarkers in food allergy linked to respiratory allergy
Villaseñor A.1, Obeso D.1, Rosace D.1, Escribese M.1, Pérez-Gordo M.1, Santaolalla M.2, Fernández-Rivas M.3, Blanco C.4,
Alvarado M.5, Dominguez C.5, Barbas C.1, Barber D.1
1. SAN PABLO CEU UNIVERSITY, Madrid, Spain
2. HOSPITAL UNIVERSITARIO SANCHINARRO, Madrid, Spain
3. HOSPITAL CLINICO SAN CARLOS, Madrid, Spain
4. HOSPITAL UNIVERSITARIO DE LA PRINCESA, Madrid, Spain
5. HOSPITAL PUBLICO VIRGEN DEL PUERTO, Plasencia, Spain
0005 Nutritional wheat alpha-amylase/trypsin inhibitors but not a control storage protein from corn exacerbate
allergen-induced gut and lung inflammation in humanized mice
Bellinghausen I.1, Weigmann B.2, Maxeiner J.3, Schuster P.3, Zevallos V.4, Reissig S.5, Waisman A.5, Schuppan D.4, Saloga J.1
1. Department of Dermatology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz,
Germany
2. Department of Internal Medicine I, University Hospital Erlangen, University of Erlangen-Nürnberg, Erlangen,
Germany
3. Asthma Core Facility, Research Center for Immunotherapy (FZI), University Medical Center of the Johannes
Gutenberg-University Mainz, Mainz, Germany
4. Institute of Translational Immunology, University Medical Center of the Johannes Gutenberg-University Mainz,
Mainz, Germany
5. Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz,
Germany
0006 Tri-pentamers in galacto-oligosaccharide mixture induce galectin-9 release in CpG dna-primed activated human
intestinal epithelial cells
Kaa M. V., Mukherjee R., Garssen J., Pieters R., Willemsen L., Kraneveld A.
Utrecht University, Utrecht, Netherlands, The

Oral Abstract Sessions
OAS 02
10:30 - 12:00
Biomarkers in asthma
Hall 3f
Chair: Stylianos Loukides, Greece
Chair: Gary Wong, Hong Kong SAR
Session roadmap
Roadmap Speaker: Stylianos Loukides, Greece
0067 Control of asthma by omalizumab: the role of CD4+Foxp3+ regulatory T cells
Amat F.1, Tallon P.2, Foray A.3, Michaud B.4, Lambert N.5, Saint-Pierre P.6, Chatenoud L.7, Just J.8
1. Department of Allergology – Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand Trousseau, Assistance
Publique-Hôpitaux de Paris, Faculté de Médecine Paris VI, INSERM UMRS1136, Paris, France
2. Department of Allergology – Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand Trousseau, Assistance
Publique-Hôpitaux de Paris, Faculté de Médecine Paris VI,, Paris, France
3. Unité 1151, INSERM & Sorbonne Paris Cité, Faculté de Médecine, Université Paris Descartes, Paris, France
4. Department of Allergology – Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand Trousseau, Assistance
Publique-Hôpitaux de Paris & Unité 1151, INSERM, Paris, France
5. Department of Allergology – Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand Trousseau, Assistance
Publique-Hôpitaux de Paris & UMRS 1136, INSERM, Paris, France
6. Institut de Mathématiques de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
7. Unité 1151, INSERM & Sorbonne Paris Cité, Faculté de Médecine, Université Paris Descartes, Paris, France, Paris,
France
8. Department of Allergology – Centre de l’Asthme et des Allergies, Hôpital d’Enfants Armand Trousseau, Assistance
Publique-Hôpitaux de Paris, Faculté de Médecine Paris VI, INSERM UMRS1136, Paris, France, Paris, France
0068 Quantification of histamine-secreting microbes from the gut differentiates obese versus non-obese asthma
patients
Barcik W., Pugin B., Westermann P., Frei R., Rodriguez N., Akdis C.
SIAF, Davos, Switzerland
0069 Decreased lung function relates to increased type-2 inflammation in asthma subjects from the Swedish ga2len
study
Mogensen I.1, Alving K.1, James A.2, Ono J.3, Ohta S.4, Izuhara K.4, Forsberg B.5, Dahlen S.2, Janson C.1, Malinovschi A.1
1. Uppsala University, Uppsala, Sweden
2. Karolinska Institute, Stockholm, Sweden
3. Shino-test Co. Ltd., Sagamihara, Japan
4. Saga Medical School, Saga, Japan
5. Umeå University, Umeå, Sweden
0070 Asthma symptoms, medication use, and lung function before and after an asthma exacerbation
Cardona V.1, Villesen H. H.2, Ljørring C.3, Rehm D.3, Smith I. M.3, Virchow J. C.4
1. Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain
2. Global Medical Affairs, ALK, Hørsholm, Denmark
3. Global Clinical Development, ALK, Hørsholm, Denmark
4. Department of Pneumology/Intensive Care Medicine, University of Rostock, Rostock, Germany
0071 Nocturnal variabilities of tidal airflow and heart rate show mutual association in young children with asthma
symptoms
Seppä V.1, Milagro J.2, Pelkonen A. S.3, Gil E.2, Lázaro J.2, Kotaniemi-Syrjänen A.3, Mäkelä M. J.3, Viik J.1, Bailón R.2, Malmberg
L. P.3
1. Biomeditech, Tampere University of Technology, Tampere, Finland
2. BSICoS group, Aragón Institute of Engineering Research (I3A), IIS Aragón, University of Zaragoza & CIBER BBN,
Zaragoza/Madrid, Spain
3. Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
0072 Phenotypes related with the clinical improvement of patients treated with omalizumab in routine clinical practice.
Fenoma study
Campo P.1, Soto-Campos J.2, Moreira A.3, Dávila I.4
1. Hospital Regional Universitario Carlos Haya, Malaga, Spain
2. Hospital Universitario de Jerez, Jerez De La Frontera, Spain
3. Novartis Farmacéutica S.A., Barcelona, Spain
4. Hospital Universitario de Salamanca, Salamanca, Spain

Oral Abstract Sessions
OAS 03
10:30 - 12:00
IgE and allergens
Hall 3g
Chair: Claudio Rhyner, Switzerland
Chair: Mohamed Shamji, United Kingdom
Session roadmap
Roadmap Speaker: Claudio Rhyner, Switzerland
0133 Human ige monoclonal antibodies with natural heavy and light chain pairing and specificity for asthma-associated
allergens
Pomés A.1, Glesner J.2, Horvath D. J.3, Wünschmann S.2, Chapman M. D.4, Smith S. A.5
1. Indoor Biotechnologies, Inc., Charlottesville, United States
2. Indoor Biotechnologies, Inc., Va, United States
3. Vanderbilt University Medical Center, Charlottesville, United States
4. Indoor Biotechnologies, Inc., Nashville, United States
5. Vanderbilt University Medical Center, Tn, United States
0134 Bet v 1 microarray: recognition pattern of serum allergen-specific IgEs
Haka J.1, Hattara L.2, Heikkinen M.2, Niemi M.3, Rouvinen J.3, Saviranta P.2, Mattila P.1, Takkinen K.2, Laukkanen M.2
1. Desentum Oy, Espoo, Finland
2. VTT Technical Research Centre of Finland Ltd., Espoo, Finland
3. University of Eastern Finland, Joensuu, Finland
0135 Identification of novel oyster allergens using a combined transcriptomic and proteomic approach for improved
diagnosis of oyster allergy
Nugraha R.1, Kamath S. D.1, Ruethers T.1, Johnston E.1, Koeberl M.2, Rolland J. M.3, O'Hehir R. E.3, Zenger K. R.4, Lopata A. L.1
1. Department of Molecular and Cell Biology, James Cook University, Townsville, Australia
2. National Measurement Institute, Melbourne, Australia
3. Department of Immunology and Pathology, Monash University, Melbourne, Australia
4. College of Marine & Environmental Science, James Cook University, Townsville, Australia
0136 Identification and immunological characterization of the ligand of pru p 3
Garrido-Arandia M., Cubells-Baeza N., Ramirez-Castillejo C., Pacios L. F., Diaz-Perales A.
Centre for Plant Biotechnology and Genomics, (UPM-INIA), Technical University of Madrid, Madrid, Spain
0137 Clonality and mast cell activation
Hoffmann H. J.1, Kragh J. H.1, Vogel M.2, Bachmann M.2
1. Aarhus University Hospital, Aarhus C, Denmark
2. University of Bern, Bern, Switzerland
0138 An anti-IgE single domain antibody disrupts the interaction of IgE with fceri by acting as functional high affinity
mimic of cd23
Jabs F.1, Plum M.1, Laursen N. S.2, Jensen R.2, Miehe M.1, Moebs C.3, Pfuetzner W.3, Jakob T.4, Andersen G. R.2, Spillner E.1
1. Department of Engineering, Aarhus University, Aarhus, Denmark
2. Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
3. Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg,
Marburg, Germany
4. Department of Dermatology and Allergology, University Medical Center Giessen and Marburg, Justus-Liebig
University Giessen, Giessen, Germany

Oral Abstract Sessions
OAS 04
10:30 - 12:00
Allergy epidemiology: Early life and environment
Room 103a
Chair: Jon Genuneit, Germany
Chair: Michael Perkin, United Kingdom
Session roadmap
Roadmap Speaker: Jon Genuneit, Germany
0169 Does leukocyte telomere length play a role as a candidate biomarker for prenatal stress exposure and the risk of
atopic dermatitis development?
Suh D.1, Choi Y.1, Koh Y.1, Kang M.2, Park Y.2, Lee J.2, Hong S.3, Sheen Y.4, Kim K.5, Ahn K.6
1. Seoul National University Children's Hospital, Seoul, South Korea
2. Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, South Korea
3. Ulsan University Asan Medical Center Department of Pediatrics, Childhood Asthma Atopy Center, Research Center
for standardization of Allergic Diseases, Seoul, South Korea
4. CHA University Kangnam CHA Hospital Department of Pediatrics, Seoul, South Korea
5. Yonsei Univeresity Severance Children's Hospital Department of Pediatrics, Seoul, South Korea
6. Sungkyunkwan University Samsung Medical Center Department of Pediatrics, Seoul, South Korea
0170 Late preterm birth protects against atopies in adulthood
Näsänen-Gilmore P.1, Sipola-Leppänen M.2, Tikanmäki M.2, Matinolli H.1, Eriksson J. G.3, Järvelin M.4, Vääräsmäki M.2, Hovi
P.1, Kajantie E.1
1. National Institute for Health and Welfare, Helsinki, Finland
2. National Institute for Health and Welfare, Oulu, Finland
3. Folkhälsan Research Centre, Helsinki, Finland
4. Imperial College London, London, United Kingdom
0171 Influence of early feeding patterns on eczema development in high-risk infants
Tang M.1, Rijnierse A.2, Nauta A.2, Boyle R.3, Hourihane J.4, Chiang W.5, Chua M.5, Smith P.6, Gold M.7, Ziegler J.8, Peake J.9,
Quinn P.7, Rao R.5, Brown N.10, Garssen J.2, Warner J.3
1. Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia
2. Nutricia Research, Utrecht, Netherlands, The
3. Imperial College, London, United Kingdom
4. University College, Cork, Ireland
5. KK Women's and Children's Hospital, Singapore City, Singapore
6. Gold Coast Hospital, Gold Coast, Australia
7. Women's and Children's Hospital, Adelaide, Australia
8. Sydney Children's Hospital, Sydney, Australia
9. Royal Children's Hospital, Brisbane, Australia
10. Salisbury Healthcare NHS Trust, Salisbury, United Kingdom
0172 Farmhouse-like indoor microbiota protects children from asthma also away from farms
Kirjavainen P. V.1, Karvonen A. M.1, Täubel M.1, Adams R.2, Jayaprakash B.1, Roponen M.3, Renz H.4, Pfefferle P.4, Schaub B.5,
Remes S.6, Hyvärinen A.1, Lauener R.7, Von Mutius E.8, Pekkanen J.9
1. THL, Kuopio, Finland
2. University of California Berkeley, Berkeley, United States
3. University of Eastern Finland, Kuopio, Finland
4. Philipps-University of Marburg, Marburg, Germany
5. Munich University, Munich, Germany
6. Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland
7. Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland
8. Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany
9. University of Helsinki, Helsinki, Finland
0173 Indoor microbiome and asthma: a case-control study within ecrhs
Pekkanen J.1, Valkonen M.2, Täubel M.2, Leppänen H.2, Kärkkäinen P.2, Rintala H.2, Zock J.3, Casas L.3, Tischer C.3, Probst-
Hensch N.4, Forsberg B.5, Holm M.6, Jahnson C.7, Pin I.8, Gíslason T.9, Jarvis D.10, Heinrich J.11, Hyvärinen A.2
1. University of Helsinki, Helsinki, Finland
2. National Institute for Health and Welfare, Kuopio, Finland
3. ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
4. Swiss Tropical and Public Health Institute, Basel, Switzerland
5. Umeå University, Umeå, Sweden
6. Sahlgrenska University Hospital, Gothenburg, Sweden
7. Uppsala University, Uppsala, Sweden
8. CHU de Grenoble Alpes, Grenoble, France
9. University of Iceland, Reykjavik, Iceland
10. Imperial College, National Heart and Lung Institute, London, United Kingdom
11. Ludwig Maximillians University, Munich, Germany
0174 Perinatal probiotics decreased eczema up to 10 years of age but at 5–10 years allergic rhino conjunctivitis was
increased
Peldan P.1, Kukkonen A. K.2, Savilahti E.1, Kuitunen M.1
1. Children´s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2. Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Oral Abstract Sessions
OAS 05
10:30 - 12:00
What's new in insect venom allergy?
Room 102
Chair: Beatrice Biló, Italy
Chair: Dario Antolin Amerigo, Spain
Session roadmap
Roadmap Speaker: Beatrice Biló, Italy
0175 Role of cytokine gene polymorphisms in hymenoptera venom allergy
Sin* B. A.1, Tutkak** H.2, Birben‡ E.3, Köse¶ K.4, Misirligil* Z.1
1. *Division of Immunology & Allergy, Ankara University School of Medicine, Ankara, Turkey
2. ** Immunology Lab., Ankara University School of Medicine, Ankara, Turkey
3. ‡ Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey
4. ¶ Dept. of Biostatistics, Ankara University School of Medicine, Ankara, Turkey
0176 Polistes venom allergy: identification and immunological characterization of novel allergens
Schiener M.1, Eberlein B.2, Hilger C.3, Kuehn A.3, Pascal M.4, Moreno-Aguilar C.5, Biedermann T.2, Darsow U.2, Schmidt-
Weber C.1, Ollert M.3, Blank S.1
1. Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich,
Munich, Germany
2. Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany
3. Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-Sur-Alzette, Luxembourg
4. Immunology Department, CDB Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
5. Hospital Universitario Reina Sofía, Córdoba, Spain
0177 Component-resolved allergen content of therapeutic honeybee venom extracts
Russkamp D.1, Etzold S.1, Darsow U.2, Schiener M.1, Eberlein B.2, Graessel A.1, Biedermann T.2, Ollert M.3, Schmidt-Weber C.
B.1, Blank S.1
1. Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich,
Munich, Germany
2. Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany
3. Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-Sur-Alzette, Luxembourg
0178 Can tests distinguish between acute patients, VIT treated patients, and asymptomatically sensitized subjects?
Schrautzer C., Arzt L., Bokanovic D., Schwarz I., Laipold K., Aberer W., Sturm G.
Department of Dermatology, Graz, Austria
0179 CD63 and CD203c expression during specific immunotherapy (SIT) for wasp venom allergy using basophile
activation test (BAT): Results after 3 years and correlation to sting challenge test
Reiß N.1, Spornraft-Ragaller P.2, Hauswald B.3, Nemat K.4, Koschel D.5, Bauer A.6, Wolf G.7, Siegert G.7, Neumeister V.7
1. Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Carl Gustav Carus, Dresden,
Germany
2. Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
3. Klinik und Poliklinik für HNO-Heilkunde, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
4. Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden,
Germany
5. Zentrum für Pneumologie, Fachkrankenhaus Coswig, Dresden, Germany
6. Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav, Dresden, Germany
7. Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Carl Gustav Carus an der TU
Dresden, Dresden, Germany
0180 Understanding health care system settings and funding structures in European countries in management of
patients with Hymenoptera venom allergy
Cichocka-Jarosz E.1, Brzyski P.2, Sturm G.3, Bilo B.4, Diwakar L.5
1. Jagiellonian University Medical College, Department of Pediatrics, Krakow, Poland
2. DZIUPLA, Statistical Analysis, Krakow, Poland
3. Medical University of Graz, Department of Dermatology, Graz, Austria
4. University Hospital Ospedali Riuniti di Ancona, Department of Internal Medicine, Ancona, Italy
5. University of Birmingham, Birmingham, United Kingdom

Poster Discussion Sessions
PDS 01
10:30 - 12:00
Urticaria and angioedema
Poster Discussion Zone 1
Chair: Clive Grattan, United Kingdom
Chair: Markus Ollert, Luxembourg
0205 Cleaved high molecular weight kininogen in plasma from patients with hereditary angioedema due to C1 inhibitor
deficiency
Sexton D. J., Faucette R., Theobald V.
Shire, Lexington, United States
0206 G protein coupled receptor kinase 2 (GRK2) regulates endothelial permeability induced by Bradykinin
Gambardella J.1, Bova M.2, Petraroli A.2, Loffredo S.2, Iaccarino G.1, Trimarco B.3, Marone G.2, Sorriento D.3, Ciccarelli M.1
1. University of Salerno, Salerno, Italy
2. Department of Translational Medical Sciences and Center for Basic and Clinical immunological Research (CISI),
University of Naples Federico II, Naples, Italy
3. University of Naples Federico II, Naples, Italy
0207 Proteomic analysis of contact system activation in plasma from patients with hereditary angioedema
Sexton D. J.1, Viswanathan M.1, Gaur T.1, Faucette R.1, Kushner H.2
1. Shire, Lexington Massachusetts, United States
2. Consultant, Shire, Lexington Massachusetts, United States
0208 Pharmacokinetics (PK) and pharmacodynamics (PD) of c1 esterase inhibitor (c1-IHN) for prophylaxis of
angioedema attacks in patients (PTS) with hereditary angioedema (HAE)
Wang Y., Martin P., Lu P., Schranz J.
Shire, Lexington, United States
0209 Gender analysis of baseline characteristics and treatment outcomes in patients (pts) with hereditary angioedema
type I/II: findings from the icatibant outcomes survey
Maurer M.1, Caballero T.2, Bouillet L.3, Aberer W.4, Grumach A. S.5, Longhurst H. J.6, Zanichelli A.7, Bygum A.8, Pommie C.9,
Andresen I.9
1. Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin,
Germany
2. Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare
Diseases (CIBERER, U754), Madrid, Spain
3. National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University Hospital,
Grenoble, France
4. Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
5. Clinical Immunology, Faculty of Medicine ABC, Santo Andre, Brazil
6. Department of Immunology, Barts Health NHS Trust, London, United Kingdom
7. Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, ASST Fatebenefratelli Sacco,
Milan, Italy
8. Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
9. Shire, Zug, Switzerland
0210 Efficacy, safety and pharmacokinetics of icatibant for acute attacks in japanese adults with type I or type II
hereditary angioedema: results of a phase 3, open-label study
Hide M.1, Fukunaga A.2, Maehara J.3, Yamamoto F.4, Hao J.5, Vardi M.5, Schranz J.5, Nomoto Y.6
1. Hiroshima University, Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima, Japan
2. Department of Dermatology, Kobe University, Kobe, Japan
3. Emergency and General Medicine Center, Saiseikai Kumamoto Hospital, Kumamoto, Japan
4. Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan
5. Shire, Lexington, United States
6. Internal Medicine Department, Niigata City General Hospital, Niigata, Japan
0211 Evaluation of IL-17 serum level in patients with chronic idiopathic urticaria based on the autologous skin test
compared to the control group
Rabeti Moghadam K.1, Nasiri Kalmarzi R.2, Moradi G.3, Babaee E.1, Fotoohi A.1, Naleini N.1, Fakhimi R.1, Kooti V.1
1. Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
2. Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
3. Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
0212 Guide clinical history for chronic urticaria: an easy tool
Chérrez Ojeda I.1, Robles Velasco K.1, Bedoya Riofrío P.1, Varas Aguilar C.1, Chérrez S.2, Chérrez A.2
1. Universidad Espíritu Santo, Guayaquil, Ecuador
2. Heidelberg University, Heidelberg, Germany
0213 Clinical and diagnostic features in acquired cold urticaria patients in a Coruña sanitary area, Spain
Veleiro Pérez B., Romero Cimas P., Pérez Quintero O., Meijide Calderón A., Rial Prado M., Garcia Paz V.
Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
0214 Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings
from visit 1 of the worldwide aware study
Maurer M.1, Berroa F.2, Castronuovo A.3, Ensina L. F.4, Guillet G.5, Houghton K. F.6, Kasujee I.3, Labrador M.7, Marsland A.8,
Mcbride D.9, Rossi O.10, Stull D. E.6, Valesco M.11, Chapman-Rothe N.3
1. Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité –Universitätsmedizin, Berlin,
Germany
2. Hospital General Plaza de la Salud, Santo Domingo, Santo Domingo, Dominican Republic
3. Novartis Pharma AG, Basel, Switzerland
4. Federal University of Sao Paulo and University of Santo Amaro, Sau Paulo, Brazil
5. Service de Dermatologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
6. RTI Health Solutions, Research Triangle Park, United States
7. Internal Medicine, Vall d’Hebron Hospital, Barcelona, Spain
8. – University of Manchester, Salford Royal NHS Foundation Trust, Salford, United Kingdom
9. RTI Health Solutions, Manchester, United Kingdom
10. SOD Immunoallergy Careggi University-Hospital, Florence, Italy
11. Dermatology Department, Hospital Arnau de Vilanova, Valencia, Spain
0215 Early impact of anti-IgE therapy on FceRI-expressing basophils in patients with chronic urticaria correlates with
improved disease control